Issue Date: July 21, 2014
Codexis Licenses Enzymes To GSK
Biocatalyst developer Codexis has licensed its enzyme engineering technology to GlaxoSmithKline for making pharmaceuticals and other health care products. GSK will pay Codexis $6 million up front and another $19 million over two years as it transfers the technology to its Upper Merion, Pa., R&D site. Under the license, GSK can use the technology to develop enzymes for manufacturing processes and to create therapeutic, diagnostic, and prophylactic products. Codexis could receive milestone payments of up to $39 million per project, plus royalties, if GSK is successful in using the technology.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society